Drugs / TBE025
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07377253 | Jan → May 2026 overdue | tick-borne encephalitis | Giuseppe Pantaleo | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TBE025 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07377253 ↗ |
| Modality | Monoclonal antibody | “TBE025 is a recombinant, fully human monoclonal antibody (mAb).” NCT07377253 ↗ |
| Route | Intravenous | “Participants will receive a single intravenous infusion of TBE025 at one of three escalating dose levels” NCT07377253 ↗ |